Form 4: Labcorp Director Victor Bulto Receives Equity Grant

Labcorp Holdings Inc. Director Victor Bulto Carulla was granted 136 Restricted Stock Units, aligning his interests with shareholders.

Summary

• Victor Bulto Carulla, a Director of Labcorp Holdings Inc., was granted 136 Restricted Stock Units (RSUs).
• Each RSU represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
• The transaction date for this acquisition was December 1, 2025.
• The RSUs will vest fully on December 1, 2026.
• Following this transaction, Victor Bulto Carulla beneficially owns 136 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of equity compensation to a director is a standard practice that aligns the director's interests with shareholders, which is generally viewed positively for corporate governance. However, it is a routine event and not indicative of significant operational or financial news.

Positives

• The grant of Restricted Stock Units to Director Victor Bulto Carulla aligns his financial interests with those of Labcorp Holdings Inc. shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for retaining and motivating key personnel and directors.

Future Outlook

The Restricted Stock Units granted to Director Victor Bulto Carulla are scheduled to vest fully on December 1, 2026, indicating a future increase in his direct beneficial ownership of common stock upon vesting.

Industry Context

The grant of Restricted Stock Units to a director is a common practice in the healthcare and diagnostics industry, as well as across publicly traded companies, to attract, retain, and incentivize board members by linking their compensation to the company's long-term stock performance. This aligns with typical corporate governance standards for director compensation.

Comparison to Industry Standards

• Equity-based compensation, such as Restricted Stock Units, is a widely adopted practice for non-employee directors across various industries, including healthcare and life sciences, to align their interests with shareholders.
• Companies like Quest Diagnostics (DGX) and other large diagnostic and laboratory services providers frequently utilize similar equity grants as part of their director compensation packages.
• The vesting schedule, typically over one to three years, is also standard, encouraging long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to a director constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to more shareholder-centric decision-making.

Next Steps

• The Restricted Stock Units will vest fully on December 1, 2026, at which point they will convert into shares of Labcorp Holdings Inc. Common Stock.

Key Dates

Keywords

Labcorp Holdings Inc., LH, Victor Bulto Carulla, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, SEC Form 4